Dr. Cui Jisong of InnoCare Pharmaceutical Co., Ltd. was awarded the Outstanding Achievement Award by the US-Chinese Medicine Development Association
September 29, 2025, Beijing, China - The 2025 Annual Meeting of the American and Chinese Medicine Development Association (SAPA) was recently held in New Jersey, USA. With the innovation achievements and various milestones achieved by leading InnoCare Pharmaceutical Co., Ltd. in the past ten years, Dr. Cui Jisong, co-founder, chairman and CEO of InnoCare Pharmaceutical Co., Ltd., was awarded the Outstanding Achievement Award (The SAPA Distinguished Achievement Award) and delivered a keynote speech themed "Ten Years of Stars and Oceans, Innovation Leads the Future", sharing that InnoCare Pharmaceutical Co., Ltd., Ltd. has developed together with the Chinese biopharmaceutical industry in the past ten years, and will continue to develop innovative drugs, consolidate commercialization and strengthen internationalization strategic goals in the future.
Dr. Cui Jisong said: "I am very grateful to SAPA for awarding this honor. It belongs to the joint efforts of all employees of InnoCare Pharmaceutical Co., Ltd.. 2025 is the 10th year of the development history of InnoCare Pharmaceutical Co., Ltd.. We have made breakthroughs in source innovation, clinical development, commercialization, production and capital markets. Entering a new era of rapid development 2.0, InnoCare Pharmaceutical Co., Ltd. is accelerating R&D and clinical trials in the global market and promoting the launch of more innovative drugs to benefit patients around the world.”
Dr. Cui Jisong has more than 25 years of experience in pharmaceutical R&D and business management. He has worked for Merck and BioDuro, a subsidiary of PPD®, and has successfully led the development and product transformation of a number of innovative drugs. Under the leadership of Dr. Cui Jisong, InnoCare Pharmaceutical Co., Ltd. has grown from an initial team of more than a dozen people to an important force in China's biopharmaceutical landscape since its establishment in 2015. In a challenging market environment, InnoCare Pharmaceutical Co., Ltd. has completed its set goals as scheduled, achieved dual A-share and Hong Kong stock listings, and built a full industry chain platform from source innovation, clinical development, production to commercialization, focusing on the development of a new class of new drugs in the field of malignant tumors and autoimmune diseases. InnoCare Pharmaceutical Co., Ltd. has independently developed a rich product pipeline. Among them, orelabrutinib (InnoCare ® ), a special result of the national "Major New Drug Development", has been approved for marketing in China and Singapore and included in China's national medical insurance. It is the first and only BTK inhibitor approved for marginal zone lymphoma in China, and tanxituzumab (InnoCare ® ) is China’s first CD19 monoclonal antibody approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma. There are also more than 10 innovative drugs in the clinical stage, including multiple pipelines that are accelerating the critical Phase III registration clinical trials.
With outstanding leadership and innovation capabilities, Dr. Cui Jisong has won many awards, including being named the most powerful business woman in China by Fortune three times, one of Forbes China's 100 Outstanding Business Women, and the "2024 Science and Technology Innovation Person of the Year" issued by Southern Weekend, etc.
About InnoCare Pharmaceutical Co., Ltd.
InnoCare Pharmaceutical Co., Ltd. (Shanghai Stock Exchange Code: 688428; Hong Kong Stock Exchange Code: 09969) is a biomedical high-tech company in the commercialization stage, focusing on the development of a new class of new drugs in the field of malignant tumors and autoimmune diseases. The company currently has multiple new drug products in the commercialization, clinical and preclinical development stages. The company has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.